Large genes including several CRISPR-Cas modules like gene activators (CRISPRa) require dual adeno-associated viral (AAV) vectors for an efficient in vivo delivery and expression. Current dual AAV vector approaches have important limitations, e.g., low reconstitution efficiency, production of alien proteins, or low flexibility in split site selection. Here, we present a dual AAV vector technology based on reconstitution via mRNA trans-splicing (REVeRT). REVeRT is flexible in split site selection and can efficiently reconstitute different split genes in numerous in vitro models, in human organoids, and in vivo. Furthermore, REVeRT can functionally reconstitute a CRISPRa module targeting genes in various mouse tissues and organs in single or multiplexed approaches upon different routes of administration. Finally, REVeRT enabled the reconstitution of full-length ABCA4 after intravitreal injection in a mouse model of Stargardt disease. Due to its flexibility and efficiency REVeRT harbors great potential for basic research and clinical applications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584818 | PMC |
| http://dx.doi.org/10.1038/s41467-023-42386-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In vivo adenine base editing ameliorates Rho-associated autosomal dominant retinitis pigmentosa.
J Genet Genomics
December 2024
MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510275, China; Key Laboratory of Reproductive Medicine of Guangdong Province, the First Affiliated Hospital and School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510275, China. Electronic address:
Mutations in the Rhodopsin (RHO) gene are the main cause of autosomal dominant retinitis pigmentosa (adRP), 84% of which are pathogenic gain-of-function point mutations. Treatment strategies for adRP typically involve silencing or ablating the pathogenic allele, while normal RHO protein replacement has no meaningful therapeutic benefit. Here, we present an adenine base editor (ABE)-mediated therapeutic approach for adRP caused by RHO point mutations in vivo.
View Article and Find Full Text PDFInterlaboratory Measurement of Adeno-Associated Virus: Comparative Quantification of Full and Empty Capsids.
Hum Gene Ther
December 2024
Prevail Therapeutics, New York, New York, USA.
Recombinant adeno-associated virus (AAV) is one of the main viral vector-based gene therapy platforms. AAV is a virus consisting of a ≈25 nm diameter capsid with a ≈4.7 kb cargo capacity.
View Article and Find Full Text PDFThe vectors went in two-by-two: Transduction efficiency and tolerability of dual and triple rAAV vector delivery following intravitreal injection for genome-editing applications.
Exp Eye Res
December 2024
Department of Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin, WI, 53226, USA; Department of Ophthalmology & Visual Sciences, Medical College of Wisconsin, WI, 53226, USA. Electronic address:
Genome or prime editing has become a promising tool for the treatment of hereditary disorders affecting the inner retina, such as dominant optic neuropathies. In vivo delivery of gene editors, such as Cas9, is typically achieved using recombinant adeno-associated virus (rAAV) vectors, which have a broad range of cellular tropisms and are well tolerated following intravitreal administration. Owing to the large size of gene editing constructs and the limited carrying capacity of rAAV (<5.
View Article and Find Full Text PDFArticle Synopsis
- - Familial dysautonomia (FD) is a serious inherited disorder caused by a specific genetic mutation that leads to neurological and systemic issues, resulting in shorter life expectancy for those affected.
- - Researchers developed a CRISPR base editor that can precisely correct the T-to-C mutation causing FD, achieving up to 70% successful editing in cell tests and improving the inclusion of a specific gene exon by over 50%.
- - The study also included an effective delivery method using engineered adeno-associated virus vectors, demonstrating that this approach can correct genetic defects in neurons and shows promise for a potential permanent treatment for FD with minimal side effects.
Determining recombinant AAV capsid extracellular and intracellular biodistribution by dual radioisotope labeling.
Mol Ther Methods Clin Dev
December 2024
National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!